Inotek Pharmaceuticals

Phathom Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

Retrieved on: 
Tuesday, June 4, 2019
Health, Biotechnology, Pharmaceutical, Professional services, Finance, General Health, Life sciences, Pharmaceutical industry, Articles, Biotechnology, Medication, Biopharmaceutical, Galmed Pharmaceuticals Ltd., Inotek Pharmaceuticals

Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders, today announced that David Socks, Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 2:00 p.m.

Key Points: 
  • Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders, today announced that David Socks, Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 2:00 p.m.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late stage development for the treatment of acid-related disorders.
  • For more information about Phathom, visit the companys website at www.phathompharma.com .

Millendo Therapeutics, Inc. to Present at the 18th Annual Needham Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2019
Health, Biotechnology, Pharmaceutical, Life sciences, Industries, Biotechnology, Inotek Pharmaceuticals

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference in New York City on Tuesday, April 9, 2019 at 12:00 p.m. EST.

Key Points: 
  • Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference in New York City on Tuesday, April 9, 2019 at 12:00 p.m. EST.
  • A live webcast of the presentation will be available on the Investors & Media section of Millendos website at http://investors.millendo.com .
  • Millendo Therapeuticsis a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient.
  • As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need.

Ocular Therapeutix™ to Host 2019 Research & Development Day

Retrieved on: 
Thursday, March 21, 2019
Surgery, Health, Biotechnology, Optical, Pharmaceutical, Research, Science, Companies, Aerie Pharmaceuticals, Inotek Pharmaceuticals

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will host a Research & Development Day to provide updates on the commercial plans for DEXTENZA and a deeper dive into the hydrogel platform and the Companys pipeline.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will host a Research & Development Day to provide updates on the commercial plans for DEXTENZA and a deeper dive into the hydrogel platform and the Companys pipeline.
  • The presentations will begin at 7:30 a.m. Eastern Time on Thursday, March 28, 2019 in New York, New York.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular pain following ophthalmic surgery.

Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference

Retrieved on: 
Tuesday, March 5, 2019
Surgery, Health, Biotechnology, Optical, Pharmaceutical, Research, Science, Aerie Pharmaceuticals, Inotek Pharmaceuticals

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael Goldstein, M.D., M.B.A., Chief Medical Officer of Ocular Therapeutix, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 8:40 AM ET at the Boston Marriott Copley Place Hotel in Boston, MA.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael Goldstein, M.D., M.B.A., Chief Medical Officer of Ocular Therapeutix, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 8:40 AM ET at the Boston Marriott Copley Place Hotel in Boston, MA.
  • Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their Cowen and Company representative.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular pain following ophthalmic surgery.

Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019

Retrieved on: 
Tuesday, January 15, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Biotechnology, Health, Urology, Biopharmaceutical, Two River, Inotek Pharmaceuticals

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019.

Key Points: 
  • Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019.
  • This event is intended for institutional investors, sell-side analysts, and business development professionals only.
  • Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
  • Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron.